OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OPK
OPKO Health, Inc. (OPK) EV/Sales
As of 16 October 2026, OPKO Health, Inc. (OPK) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.7× (December 2022) to 84.0× (June 2015); the current reading is higher than 60% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | 5.62% |
| FY2024 | 1.4× | (6.63%) |
| FY2023 | 1.5× | 58.80% |
| FY2022 | 1.0× | (46.12%) |
| FY2021 | 1.8× | (5.16%) |
| FY2020 | 1.9× | 68.87% |
| FY2019 | 1.1× | (34.46%) |
| FY2018 | 1.7× | (39.46%) |
| FY2017 | 2.8× | (35.51%) |
| FY2016 | 4.4× | (54.87%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | 34.48% |
| Mar 2026 | 1.5× | (1.49%) |
| Dec 2025 | 1.5× | (20.27%) |
| Sep 2025 | 1.9× | 5.44% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| FLGT Fulgent Genetics, Inc. compare | 1.0× |
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. | 2.0× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| CDNA CareDx, Inc. compare | 6.4× |
| PSNL Personalis, Inc. compare | 20.9× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)